Lilly, Ascidian Link up in RNA Exon Editing Pact

Eli Lilly is striking a $1.9 billion gene-editing deal to develop inherited kidney disease treatments

The agreement gives Lilly exclusive rights to Ascidian's RNA exon-editing technology, which repairs faulty genes without altering a patient's DNA

Lilly strikes $1.9bn kidney disease alliance with Ascidian

In its third big licensing deal of the week, Eli Lilly has tapped RNA-editing specialist Ascidian for kidney disease therapies in a $1.9bn alliance.

Ascidian and Lilly Enter Global Research Collaboration to Develop RNA Exon Editors for Devastating Kidney Diseases

Combines Ascidian's RNA exon editing product engine with Lilly's leadership in genetic medicines

Lilly, Ascidian link up in RNA exon editing pact

Worth as much as $1.9 billion, the deal directs Ascidian to help Lilly find potential drugs for genetically driven kidney diseases.